Jonathan Gerber, founder of the Jerusalem Portfolio, interviews Assaf Oron, Chief Business Officer at Biomx
Biomx is a clinical-stage microbiome company that is developing phage therapies designed to target and destroy harmful bacteria in chronic diseases, such as inflammatory bowel disease and colorectal cancer. The microbiome – all of the microbes (bacteria, archaea, viruses, and fungi) that reside in and on the human body – is a new and fast-developing field that offers many opportunities for the development of new medicine. Bacteriophages (or phages) are viruses that solely kill and selectively target bacteria without harming good microbiome.
For more information, please visit www.biomx.com